Home > Research > Publications & Outputs > Molecular Origins of the Compatibility Between ...

Electronic data

  • 1-s2.0-S0022283617303388-main

    Rights statement: This is the author’s version of a work that was accepted for publication in Journal of Molecular Biology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Molecular Biology, 429, 16, 2017 DOI: 10.1016/j.jmb.2017.07.003

    Accepted author manuscript, 699 KB, PDF document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils. / Stewart, Katie L.; Hughes, Eleri; Yates, Edwin A. et al.
In: Journal of Molecular Biology, Vol. 429, No. 16, 04.08.2017, p. 2449-2462.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Stewart, KL, Hughes, E, Yates, EA, Middleton, DA & Radford, SE 2017, 'Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils', Journal of Molecular Biology, vol. 429, no. 16, pp. 2449-2462. https://doi.org/10.1016/j.jmb.2017.07.003

APA

Vancouver

Stewart KL, Hughes E, Yates EA, Middleton DA, Radford SE. Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils. Journal of Molecular Biology. 2017 Aug 4;429(16):2449-2462. Epub 2017 Jul 10. doi: 10.1016/j.jmb.2017.07.003

Author

Stewart, Katie L. ; Hughes, Eleri ; Yates, Edwin A. et al. / Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils. In: Journal of Molecular Biology. 2017 ; Vol. 429, No. 16. pp. 2449-2462.

Bibtex

@article{62133f4f1d754a5eb9b832447bdf34bb,
title = "Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils",
abstract = "The Aβ peptide forms extracellular plaques associated with Alzheimer's disease. In addition to protein fibrils, amyloid plaques also contain non-proteinaceous components, including glycosaminoglycans (GAGs). We have shown previously that the GAG low molecular weight heparin (LMWH) binds to Aβ40 fibrils with a three-fold-symmetric (3Q) morphology with higher affinity than Aβ40 fibrils in alternative structures, Aβ42 fibrils, or amyloid fibrils formed from other sequences. Solid-state NMR (SSNMR) analysis of the GAG-3Q fibril complex revealed an interaction site at the corners of the 3Q fibril structure, but the origin of the binding specificity remained obscure. Here, employing a library of short heparin polysaccharides modified at specific sites, we show that the NS or 6-OS glucosamine sulfates, but not the 2-OS iduronate sulfate, of heparin is required for 3Q binding, indicating selectivity in the interactions of the GAG with the fibril that extends beyond general electrostatic complementarity. By creating 3Q fibrils containing point substitutions in the amino acid sequence, we also show that charged residues at the fibril three-fold apices provide the majority of the binding free energy, while charged residues elsewhere are less critical for binding. The results indicate, therefore, that LMWH binding to 3Q fibrils requires a precise molecular complementarity of the sulfate moieties on the GAG and charged residues displayed on the fibril surface. Differences in GAG binding to fibrils with distinct sequence and/or structure may thus contribute to the diverse etiology and progression of amyloid diseases.",
keywords = "amyloid β, glycosaminoglycans, Alzheimer's disease, amyloid fibrils, heparin binding",
author = "Stewart, {Katie L.} and Eleri Hughes and Yates, {Edwin A.} and Middleton, {David A.} and Radford, {Sheena E.}",
note = "This is the author{\textquoteright}s version of a work that was accepted for publication in Journal of Molecular Biology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Molecular Biology, 429, 16, 2017 DOI: 10.1016/j.jmb.2017.07.003",
year = "2017",
month = aug,
day = "4",
doi = "10.1016/j.jmb.2017.07.003",
language = "English",
volume = "429",
pages = "2449--2462",
journal = "Journal of Molecular Biology",
issn = "0022-2836",
publisher = "Academic Press Inc.",
number = "16",

}

RIS

TY - JOUR

T1 - Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils

AU - Stewart, Katie L.

AU - Hughes, Eleri

AU - Yates, Edwin A.

AU - Middleton, David A.

AU - Radford, Sheena E.

N1 - This is the author’s version of a work that was accepted for publication in Journal of Molecular Biology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Molecular Biology, 429, 16, 2017 DOI: 10.1016/j.jmb.2017.07.003

PY - 2017/8/4

Y1 - 2017/8/4

N2 - The Aβ peptide forms extracellular plaques associated with Alzheimer's disease. In addition to protein fibrils, amyloid plaques also contain non-proteinaceous components, including glycosaminoglycans (GAGs). We have shown previously that the GAG low molecular weight heparin (LMWH) binds to Aβ40 fibrils with a three-fold-symmetric (3Q) morphology with higher affinity than Aβ40 fibrils in alternative structures, Aβ42 fibrils, or amyloid fibrils formed from other sequences. Solid-state NMR (SSNMR) analysis of the GAG-3Q fibril complex revealed an interaction site at the corners of the 3Q fibril structure, but the origin of the binding specificity remained obscure. Here, employing a library of short heparin polysaccharides modified at specific sites, we show that the NS or 6-OS glucosamine sulfates, but not the 2-OS iduronate sulfate, of heparin is required for 3Q binding, indicating selectivity in the interactions of the GAG with the fibril that extends beyond general electrostatic complementarity. By creating 3Q fibrils containing point substitutions in the amino acid sequence, we also show that charged residues at the fibril three-fold apices provide the majority of the binding free energy, while charged residues elsewhere are less critical for binding. The results indicate, therefore, that LMWH binding to 3Q fibrils requires a precise molecular complementarity of the sulfate moieties on the GAG and charged residues displayed on the fibril surface. Differences in GAG binding to fibrils with distinct sequence and/or structure may thus contribute to the diverse etiology and progression of amyloid diseases.

AB - The Aβ peptide forms extracellular plaques associated with Alzheimer's disease. In addition to protein fibrils, amyloid plaques also contain non-proteinaceous components, including glycosaminoglycans (GAGs). We have shown previously that the GAG low molecular weight heparin (LMWH) binds to Aβ40 fibrils with a three-fold-symmetric (3Q) morphology with higher affinity than Aβ40 fibrils in alternative structures, Aβ42 fibrils, or amyloid fibrils formed from other sequences. Solid-state NMR (SSNMR) analysis of the GAG-3Q fibril complex revealed an interaction site at the corners of the 3Q fibril structure, but the origin of the binding specificity remained obscure. Here, employing a library of short heparin polysaccharides modified at specific sites, we show that the NS or 6-OS glucosamine sulfates, but not the 2-OS iduronate sulfate, of heparin is required for 3Q binding, indicating selectivity in the interactions of the GAG with the fibril that extends beyond general electrostatic complementarity. By creating 3Q fibrils containing point substitutions in the amino acid sequence, we also show that charged residues at the fibril three-fold apices provide the majority of the binding free energy, while charged residues elsewhere are less critical for binding. The results indicate, therefore, that LMWH binding to 3Q fibrils requires a precise molecular complementarity of the sulfate moieties on the GAG and charged residues displayed on the fibril surface. Differences in GAG binding to fibrils with distinct sequence and/or structure may thus contribute to the diverse etiology and progression of amyloid diseases.

KW - amyloid β

KW - glycosaminoglycans

KW - Alzheimer's disease

KW - amyloid fibrils

KW - heparin binding

U2 - 10.1016/j.jmb.2017.07.003

DO - 10.1016/j.jmb.2017.07.003

M3 - Journal article

VL - 429

SP - 2449

EP - 2462

JO - Journal of Molecular Biology

JF - Journal of Molecular Biology

SN - 0022-2836

IS - 16

ER -